Chaki S - Search Results

1

Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test.

Shimazaki T, Iijima M, Chaki S. Shimazaki T, et al. Among authors: chaki s. Eur J Pharmacol. 2004 Oct 6;501(1-3):121-5. doi: 10.1016/j.ejphar.2004.08.016. Eur J Pharmacol. 2004. PMID: 15464070

2

5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices.

Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H. Muramatsu M, et al. Among authors: chaki s. Eur J Pharmacol. 1988 Aug 9;153(1):89-95. doi: 10.1016/0014-2999(88)90591-2. Eur J Pharmacol. 1988. PMID: 2975224

3

Discrimination of (+)-3-PPP sites from DTG sites by FH-510, a novel potent sigma ligand, in rat brain.

Chaki S, Tanaka M, Muramatsu M, Otomo S. Chaki S, et al. Eur J Pharmacol. 1993 Nov 30;250(1):173-5. doi: 10.1016/0014-2999(93)90638-x. Eur J Pharmacol. 1993. PMID: 7907020

4

FH-510, a potent and selective ligand for rat brain sigma recognition sites.

Tanaka M, Chaki S, Imagawa Y, Okuyama S, Muramatsu M, Otomo S. Tanaka M, et al. Among authors: chaki s. Eur J Pharmacol. 1993 Jul 6;238(1):89-92. doi: 10.1016/0014-2999(93)90509-g. Eur J Pharmacol. 1993. PMID: 8104803

5

Binding characteristics of [3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors.

Chaki S, Funakoshi T, Yoshikawa R, Okuyama S, Okubo T, Nakazato A, Nagamine M, Tomisawa K. Chaki S, et al. Eur J Pharmacol. 1999 Apr 29;371(2-3):197-204. doi: 10.1016/s0014-2999(99)00118-1. Eur J Pharmacol. 1999. PMID: 10357257

6

In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.

Chaki S, Okuyama S, Nakazato A, Kumagai T, Okubo T, Ikeda Y, Oshida Y, Hamajima Y, Tomisawa K. Chaki S, et al. Eur J Pharmacol. 1999 Apr 29;371(2-3):205-11. doi: 10.1016/s0014-2999(99)00120-x. Eur J Pharmacol. 1999. PMID: 10357258

7

Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.

Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S. Nakazato A, et al. Among authors: chaki s. J Med Chem. 2000 Dec 14;43(25):4893-909. doi: 10.1021/jm000346k. J Med Chem. 2000. PMID: 11123999

8

Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats.

Kawashima N, Funakoshi T, Omura T, Chaki S, Kameo K, Okuyama S. Kawashima N, et al. Among authors: chaki s. Eur J Pharmacol. 2001 Jun 29;423(1):27-33. doi: 10.1016/s0014-2999(01)01085-8. Eur J Pharmacol. 2001. PMID: 11438303

9

Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.

Chaki S, Hirota S, Funakoshi T, Suzuki Y, Suetake S, Okubo T, Ishii T, Nakazato A, Okuyama S. Chaki S, et al. J Pharmacol Exp Ther. 2003 Feb;304(2):818-26. doi: 10.1124/jpet.102.044826. J Pharmacol Exp Ther. 2003. PMID: 12538838

10

Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents.

Chaki S, Kawashima N, Suzuki Y, Shimazaki T, Okuyama S. Chaki S, et al. Eur J Pharmacol. 2003 Mar 7;464(1):49-54. doi: 10.1016/s0014-2999(03)01368-2. Eur J Pharmacol. 2003. PMID: 12600694

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page